

Hospital, Fluminense Federal University, Niterói,  
Rio de Janeiro, Brazil

<sup>2</sup>Retina and Vitreous Unit, Department of  
Ophthalmology, Federal University of Rio Grande  
do Norte, Natal, Brazil

Correspondence: RNG Vianna,  
Rua João Pessoa, 346/201,  
Jardim Icaraí—Niterói—Rio De Janeiro, CEP:  
24220-331, Brazil  
Tel/Fax: + 55 21 2610 1452.  
E-mail: raulngvianna@ig.com.br

None of the authors has a proprietary or financial  
interest in the products or techniques described in  
this article

*Eye* (2006) 20, 1113–1116. doi:10.1038/sj.eye.6702154;  
published online 11 November 2005


Sir,  
**Decreased vision as the initial presenting symptom of  
disseminated prostatic disease**

Soft tissue solitary choroidal masses of the eye as the  
initial presenting symptom of disseminated metastatic  
disease is rare. We present the case of a 52-year old who  
presented with visual symptoms relating to a prostatic  
adenocarcinoma primary, who responded clinically with  
external beam radiotherapy. The presentation and  
infrequency of such presentations is discussed.

**Case report**

A 52-year old presented with a 1-week history of a  
painless decrease in visual acuity in his right eye, of  
gradual onset. Past ocular history was remarkable for  
anisometropic amblyopia of the left eye. Examination  
revealed an unaided Snellen visual acuity of 6/60 right  
and 6/18 left. Anterior segment examination was  
normal. Fundal examination revealed a solitary elevated  
solid mass lesion superiorly with an overlying exudative  
retinal detachment, involving the macula (Figure 1). On  
systems review, the patient revealed a 6-week history of  
low back pain and nocturia and right-calf pain for 5 days.

B-scan ultrasound examination revealed a 5 mm  
(high) × 13 mm homogenous mass with choroidal  
excavation (Figure 2). A metastatic screen with CT  
imaging revealed extensive systemic metastases  
including a retropharyngeal mass, para-aortic adenopathy,  
bilateral hydronephrosis, bony lytic secondaries in




**Figure 1** Superior lesion (black arrow) with overlying exudative retinal detachment involving the macula (white arrow).



**Figure 2** B-scan ultrasound showing an elevated, solid, homogenous mass with choroidal excavation with calcified area in the anterior pole of the lesion.

lumbar vertebrae 3 and sacroiliac joints with an osteolytic  
appearance from a presumed prostatic carcinoma  
primary (Figures 3a–d). Dopplers of the right lower limb  
confirmed a deep vein thrombosis secondary to pelvic  
compression. Serology revealed an elevated prostate-  
specific antigen (PSA) at 104 ng/dl, and renal  
impairment with a creatinine of 135. Liver function tests  
revealed an elevated alkaline phosphatase. Clinical  
examination (urology) revealed a T4 prostatic carcinoma.  
Ultrasound-guided biopsy confirmed prostatic  
adenocarcinoma on histopathology, with a Gleeson  
rating of 9.



**Figure 3** CT scan showing disseminated metastatic disease indicated by arrow. (a) Lesion in the posterior pole (white arrow). (b) Lesion on medial aspect of the sacroiliac joint. (c) Lytic lesion in L3. (d) Carcinomatous prostate.



**Figure 4** Regressed fundal lesion with resolution of the serous detachment. Note the retinal pigment change over the radiated area (black arrow).

The treatment consisted of total androgen blockade, anticoagulation and oral dexamethasone and radiotherapy to the bony and pelvic secondaries. External beam radiotherapy of 30 Gy in 10 divided doses to the orbit lead to regression of the chorio-retinal lesion

with resolution of sub-retinal fluid and an improvement of visual acuity to 6/9 (Figure 4).

#### Comment

Metastatic disease from the prostate to the orbit and ocular structures is rare.<sup>1-5</sup> Visual symptoms as the presenting, initial feature of disseminated malignancy is rare and few case reports exist in the literature. De Potter *et al*<sup>4</sup> examined 379 patients with uveal metastases and found 2% (seven patients) with prostatic carcinoma previously diagnosed. No patients had initially presented with visual symptoms. Shields *et al*<sup>1</sup> examined 920 patients with uveal metastases and found that 66% had previously been diagnosed with cancer, and that of the remaining 38%, none had a prostatic primary. The ocular prognosis for resolution is not dependent on the grade of the tumour and prostatic adeno-carcinoma is radiosensitive. Radiotherapy to the orbit is the standard treatment for secondary ocular neoplasms including the prostate. Transpupillary thermotherapy (TTT) may be considered and a recent report by Kiratli *et al*,<sup>6</sup> demonstrated that resolution of choroidal metastases could be achieved with TTT where the primary tumours included lung, breast and prostate. They found that lesions greater than 3.5 mm high responded poorly and necessitated radiotherapy. We present a patient who presented with a solitary choroidal tumour secondary to

a previously unknown prostatic primary with a good visual outcome post treatment.

### References

- 1 Shields CL, Shields JA, Gross NE, Schwartz GP, Lally SE. Survey of 520 eyes with uveal metastases. *Ophthalmology* 1997; **104**(8): 1265–1276.
- 2 Bonillo Garcia MA, Queipo Zaragoza JA, Palmero Marti JA, Pacheco Bru JJ, Vera Sempere FJ, Jimenez Cruz JF. Retroorbital metastasis an initial manifestation of prostatic cancer. *Actas Urol Esp* 2003; **27**(7): 562–565.
- 3 Giannakopoulos X. Orbital metastasis from prostatic carcinoma. *Urol Int* 2003; **70**(3): 219–222.
- 4 De Potter P, Shield CL. Uveal metastases from prostatic carcinoma. *Cancer* 1993; **71**: 2791–2796.
- 5 Bates AW, Baithun SI. Secondary solid neoplasms of the prostate: a clinico-pathological series of 51 cases. *Virchows Arch* 2002; **440**(4): 392–396.
- 6 Kiratli H, Bilgic S. Transpupillary thermotherapy in the management of choroidal metastases. *Eur J Ophthalmol* 2004; **14**(5): 423–437.

PP Connell<sup>1</sup>, K Fennessy<sup>1</sup>, T Elfiki<sup>1</sup>, C Bogue<sup>1</sup>, S O'Reilly<sup>2</sup> and S Fenton<sup>2</sup>

<sup>1</sup>Royal Victoria Eye and Ear Hospital, Adelaide Rd, Dublin 4, Ireland

<sup>2</sup>Cork University Hospital, Oncology Department, Wilton Road, Cork, Ireland

Correspondence: PP Connell,  
Tel: +86 812 1494;  
Fax: +353 1 676 1858.  
E-mail: drpaulconnell@gmail.com

*Eye* (2006) **20**, 1116–1118. doi:10.1038/sj.eye.6702155;  
published online 18 November 2005